Skip to NavigationSkip to content


Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund

MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy in the first-line treatment of untreated metastatic squamous non-small cell lung cancer (NSCLC), it has emerged.

The final appraisal determination marks the first for a immunotherapy/chemotherapy combo in this indication regardless of PD-L1 expression.

BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund

NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to patients in England via the Cancer Drugs Fund (CDF) for the first-line treatment of untreated renal cell carcinoma (RCC), the most common form of kidney cancer.

The drug’s immediate availability through this new pathway provides RCC with another treatment option, which is particularly meaningful as current NHS standard of treatment such as pazopanib, sunitinib, tivozanib or cabozantinib are associated with side-effects including hand and

NICE recommends Eli Lilly's Verzenio in combination with Fulvestrant for breast cancer

Britain’s cost effectiveness body, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly’s Verzenio (abemaciclib) in combination with Fulvestrant, for women with advanced breast cancer. The drug will be available to NHS patients through the Cancer Drugs Fund (CDF).

The treatment could be an option for as many as 4,800 women who have already had endocrine treatment for hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body.

Cancer Drugs Fund to offer MSD's Keytruda for lung cancer

MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces it has agreed to recommend the drug in treatment-naive non-small-cell lung cancer, whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.

The submission of evidence to support the drug’s benefits drove the decision, showing that Keytruda improvised progression-free survival by around four months compared to standard of care pemetrexed with platinum chemotherapy, allowing NICE to determine that

BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer

Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for inclusion in the Cancer Drugs Fund (CDF) for the treatment of squamous cell carcinoma of the head and neck which has metastasized in patients who have not responded to chemotherapy within six months.

NICE gives final draft guidance on two key cancer drugs

NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the treatment of gastrointestinal stromal tumours (GIST), and Roche’s Erivedge (vismodegib) in the treatment of advanced basal cell carcinoma (BCC) that cannot be treated with surgery or radiotherapy.

Roche antibody becomes first of its kind authorised for blood cancer

NICE has announced its decision to make Roche’s Gazyvaro available via the Cancer Drugs Fund (CDF) in combination with chemotherapy for the treatment of follicular lymphoma. The move opens the treatment up to around 600 UK citizens living with the disease.

Specifically, the drug is authorised to be administered with bendamustine followed by obinutuzumab maintenance in those who failed to respond or who progressed during or up to six months after being treated with Roche’s rituximab.

Price cuts bring 14 Cancer Drugs Fund treatments into routine NHS use

NICE has revealed that it has reached the halfway point in its review of the old Cancer Drugs Fund (CDF) with the goal of making its drugs available for routine use. So far, with the latest recommendation this week of Merck’s Erbitux (cetuximab) and Amgen’s Vectibix (panitumumab) for bowel cancer, the institute has approved 14 drugs across 18 indications for use across NHS England and Wales.

NICE recommends Novartis' previously CDF-exclusive kidney cancer treatment

In a reappraisal decision by NICE, everolimus (Novartis’ Afinitor) has been recommended for the treatment of advanced renal cell carcinoma (RCC) in patients who have not responded to initial treatment and have seen their disease progress.  

A once-daily oral pill, Afinitor prevents the spread of tumours by interrupting the growth of new blood vessels within them, helping to treat the kidney cancer RCC, which can in advanced cases spread to other parts of the kidney and even the lymph glands.

Insider interview: Roche discusses efficacy of CDF and NICE

Deborah Lancaster, Head of Market Access at Roche, discusses, in the latest issue of Pharmafile, the efficacy of the National Institute of Health and Care Excellence (NICE) and the reformed Cancer Drugs Fund (CDF) for pharma companies seeking drug approval in England and Wales.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches